Incepta Vaccine

Executive Summary

Incepta Vaccine, Bangladesh’s first human vaccine producer and a subsidiary of Incepta Pharmaceuticals, operates a WHO-GMP-compliant facility in Savar, Dhaka. Founded in 2020, the company manufactures affordable vaccines such as Vaxitet (tetanus) and focuses on developing indigenous vaccines tailored to local disease burdens. With a full cold-chain system, a large animal house for preclinical testing, and a dedicated R&D unit, Incepta Vaccine aims to enhance immunization coverage in Bangladesh and neighboring regions. As a commercial-stage private company with 200-500 employees, it plays a critical role in reducing vaccine import dependency.

Upcoming Catalysts (preview)

• Q2 2027WHO prequalification of Vaxitet (tetanus vaccine) enabling global procurement70% success
• Q4 2026Partnership or licensing agreement for COVID-19 vaccine fill-and-finish or local production60% success
• Q3 2027Launch of a new locally developed combination vaccine (e.g., DTwP-Hib) with government approval50% success